These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 22074425)

  • 41. Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination.
    Sharma SK; Bagshawe KD
    Expert Opin Biol Ther; 2017 Jan; 17(1):1-13. PubMed ID: 27737561
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tumor targeting: activation of prodrugs by enzyme-monoclonal antibody conjugates.
    Huennekens FM
    Trends Biotechnol; 1994 Jun; 12(6):234-9. PubMed ID: 7765070
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
    Roy P; Waxman DJ
    Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy.
    Masterson LA; Spanswick VJ; Hartley JA; Begent RH; Howard PW; Thurston DE
    Bioorg Med Chem Lett; 2006 Jan; 16(2):252-6. PubMed ID: 16290933
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Targeting of antitumor drugs with monoclonal antibodies].
    Monneret C; Florent JC
    Bull Cancer; 2000 Nov; 87(11):829-38. PubMed ID: 11125291
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Duocarmycin-based prodrugs for cancer prodrug monotherapy.
    Tietze LF; Schuster HJ; Schmuck K; Schuberth I; Alves F
    Bioorg Med Chem; 2008 Jun; 16(12):6312-8. PubMed ID: 18524605
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advances in prodrug design.
    Silva AT; Chung MC; Castro LF; Güido RV; Ferreira EI
    Mini Rev Med Chem; 2005 Oct; 5(10):893-914. PubMed ID: 16250833
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
    Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
    Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents.
    Devkota L; Lin CM; Strecker TE; Wang Y; Tidmore JK; Chen Z; Guddneppanavar R; Jelinek CJ; Lopez R; Liu L; Hamel E; Mason RP; Chaplin DJ; Trawick ML; Pinney KG
    Bioorg Med Chem; 2016 Mar; 24(5):938-956. PubMed ID: 26852340
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enzyme-catalyzed activation of anticancer prodrugs.
    Rooseboom M; Commandeur JN; Vermeulen NP
    Pharmacol Rev; 2004 Mar; 56(1):53-102. PubMed ID: 15001663
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite.
    Bridgewater JA; Knox RJ; Pitts JD; Collins MK; Springer CJ
    Hum Gene Ther; 1997 Apr; 8(6):709-17. PubMed ID: 9113510
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prodrug-activating systems in suicide gene therapy.
    Springer CJ; Niculescu-Duvaz I
    J Clin Invest; 2000 May; 105(9):1161-7. PubMed ID: 10791987
    [No Abstract]   [Full Text] [Related]  

  • 54. Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT).
    Hay MP; Wilson WR; Denny WA
    Bioorg Med Chem Lett; 1999 Dec; 9(24):3417-22. PubMed ID: 10617083
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aerobic nitroreduction by flavoproteins: enzyme structure, mechanisms and role in cancer chemotherapy.
    Skelly JV; Knox RJ; Jenkins TC
    Mini Rev Med Chem; 2001 Sep; 1(3):293-306. PubMed ID: 12369976
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
    Biela BH; Khawli LA; Hu P; Epstein AL
    Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).
    Springer CJ; Dowell R; Burke PJ; Hadley E; Davis DH; Blakey DC; Melton RG; Niculescu-Duvaz I
    J Med Chem; 1995 Dec; 38(26):5051-65. PubMed ID: 8544182
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Potentiation of antitumor immunity by antibody-directed enzyme prodrug therapy.
    Chen BM; Cheng TL; Tzou SC; Roffler SR
    Int J Cancer; 2001 Dec; 94(6):850-8. PubMed ID: 11745488
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy.
    Heinis C; Alessi P; Neri D
    Biochemistry; 2004 May; 43(20):6293-303. PubMed ID: 15147213
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Strategies in the designing of prodrugs, taking into account the antiviral and anticancer compounds.
    Lesniewska-Kowiel MA; Muszalska I
    Eur J Med Chem; 2017 Mar; 129():53-71. PubMed ID: 28219047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.